Vancomycin-induced nephrotoxicity. Toxic nephropathy, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: For people in the case group, lycopene tablets 15 mg with vancomycin will be prescribed once a day. Intervention 2: Control group: For control group participants, p
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Serum creatinine levels less than 1.2 mg / dl at the start of the study Creatinine clearance (ClCr)> 90 ml / min upon admission Lack of underlying renal impairment such as glomerulonephritis, polycystic kidney disease, kidney stones, interstitial nephritis, renal artery stenosis and renal carcinoma Lack of underlying diseases causes kidney disorders such as diabetes mellitus and high blood pressure Hospital history and failure to receive other nephrotoxic drugs such as aminoglycosides, amphotericin B, cyclosporine, tacrolimus and furosemide, etc. Do not take other antioxidant supplements such as vitamins C and E.
Exclusion criteria
Exclusion criteria: History of acute kidney damage Lycopene allergy history History of injectable addiction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum creatinine. Timepoint: Before starting treatment, one day between treatments and 12 hours after the last dose of vancomycin on the tenth day of treatment. Method of measurement: Photometric.;Blood urea nitrogen. Timepoint: Before starting treatment, one day between treatments and 12 hours after the last dose of vancomycin on the tenth day of treatment. Method of measurement: Photometric.;Creatinine clearance. Timepoint: Before starting treatment, one day between treatments and 12 hours after the last dose of vancomycin on the tenth day of treatment. Method of measurement: Cockcroft-Gault formula. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSomaye Haghighipour
Esfahan University of Medical Sciences
Outcome results
None listed